A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer
1998

Efficacy of Paclitaxel in Heavily Pretreated Small-Cell Lung Cancer Patients

Sample size: 24 publication Evidence: moderate

Author Information

Author(s): EF Smit, E Fokkema, B Biesma, HJM Groen, W Snoek, PE Postmus

Primary Institution: University Hospital Groningen

Hypothesis

The study aims to evaluate the efficacy and toxicity of paclitaxel in patients with drug-resistant small-cell lung cancer.

Conclusion

Paclitaxel is active in drug-resistant small-cell lung cancer, showing a 29% partial response rate with manageable toxicity.

Supporting Evidence

  • Of 24 patients, 7 had a partial response to treatment.
  • The median survival time was 100 days.
  • Life-threatening toxicity occurred in four patients, but most side effects were manageable.
  • Paclitaxel was administered for a maximum of five cycles.

Takeaway

This study tested a cancer drug called paclitaxel on patients whose lung cancer didn't respond to other treatments, and it helped some of them feel better.

Methodology

Patients received paclitaxel 175 mg/m² intravenously every 3 weeks, with dose adjustments based on toxicity.

Potential Biases

Potential bias due to the lack of a control group and the open-label design.

Limitations

The study had a small sample size and included patients with varying degrees of prior treatment.

Participant Demographics

Median age was 56 years (range 39-73), with 83% male participants.

Statistical Information

Confidence Interval

95% CI 12-51%

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication